Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The current standard of care for unresectable locally advanced non-small-cell lung cancer
(NSCLC) is a combination of chemotherapy and thoracic radiotherapy (TRT). The standard
regimens consist of platinum-based doublet chemotherapy.Icotinib(BPI-2009, Conmana) is the
first self-developed small molecular drug in China for targeted therapy of lung
cancer.Icotinib is a novel oral quinazoline compound that has proven survival benefit in
Chinese patients with lung cancer,especially in EGFR mutation lung cancer. This randomised,
multi-center, controlled trial is designed to assess the efficacy and safety of icotinib with
concurrent radiotherapy versus pemetrexed + carboplatin with concurrent radiotherapy in
inoperable stage III non-small cell lung cancer with EGFR mutation, the primary endpoint is
progression-free survival.